ProPhase Labs (PRPH) Short Interest Ratio & Short Volume $0.63 0.00 (-0.57%) (As of 12/24/2024 03:33 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ProPhase Labs Short Interest DataProPhase Labs (PRPH) has a short interest of 144,900 shares. This marks a -41.03% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.0, indicating that it would take 1.0 days of the average trading volume of 74,594 shares to cover all short positions.Current Short Interest144,900 sharesPrevious Short Interest245,700 sharesChange Vs. Previous Month-41.03%Dollar Volume Sold Short$111,573.00Short Interest Ratio1.0 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares23,874,000 sharesPercentage of Shares Shorted0.61%Today's Trading Volume41,125 sharesAverage Trading Volume74,594 sharesToday's Volume Vs. Average55% Short Selling ProPhase Labs? Sign up to receive the latest short interest report for ProPhase Labs and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPRPH Short Interest Over TimePRPH Days to Cover Over TimePRPH Percentage of Float Shorted Over Time Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. ProPhase Labs Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/2024144,900 shares $111,573.00 -41.0%N/A1 $0.77 11/15/2024245,700 shares $184,275.00 +59.4%N/A2.1 $0.75 10/31/2024154,100 shares $352,889.00 -25.2%N/A1.9 $2.29 10/15/2024206,100 shares $471,969.00 -10.8%N/A7.1 $2.29 9/30/2024231,000 shares $559,020.00 -9.9%N/A7.7 $2.42 9/15/2024256,300 shares $627,935.00 +3.0%N/A8.1 $2.45 Get the Latest News and Ratings for PRPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024248,900 shares $669,541.00 -9.9%N/A8.4 $2.69 8/15/2024276,300 shares $624,438.00 -13.3%N/A8.5 $2.26 7/31/2024318,500 shares $974,610.00 +0.7%N/A9.4 $3.06 7/15/2024316,400 shares $1.02 million -1.8%N/A8.6 $3.22 6/30/2024322,300 shares $1.35 million +0.5%N/A5.4 $4.18 6/15/2024320,800 shares $1.47 million +2.1%N/A5.3 $4.59 5/31/2024314,200 shares $1.62 million +20.8%N/A5.2 $5.15 5/15/2024260,100 shares $1.34 million -1.9%N/A4.3 $5.14 4/30/2024265,100 shares $1.22 million -3.5%1.9%5 $4.61 4/15/2024274,700 shares $1.69 million +6.8%2.0%5.5 $6.16 3/31/2024257,300 shares $1.66 million +3.7%1.8%9.6 $6.47 3/15/2024248,200 shares $1.25 million -16.9%1.8%9.5 $5.04 2/29/2024298,500 shares $1.33 million +0.7%2.1%11.2 $4.47 2/15/2024296,400 shares $1.47 million -0.2%2.1%12.1 $4.96 1/31/2024297,000 shares $1.44 million +4.7%2.1%11.2 $4.85 1/15/2024283,600 shares $1.39 million -7.3%2.0%10.9 $4.90 12/31/2023306,000 shares $1.38 million -5.1%2.2%12.2 $4.52 12/15/2023322,400 shares $1.45 million -20.2%2.3%13.1 $4.50 11/30/2023404,000 shares $2.05 million +45.5%2.9%15.2 $5.07 11/15/2023277,700 shares $1.21 million -5.3%2.0%8.8 $4.35 10/31/2023293,100 shares $1.29 million -1.9%2.3%7.9 $4.39 10/15/2023298,800 shares $1.31 million -3.9%2.3%7.7 $4.37 9/30/2023311,000 shares $1.36 million +0.2%2.4%7.5 $4.37 9/15/2023310,300 shares $1.41 million -13.8%2.4%7.1 $4.56 8/31/2023360,100 shares $1.54 million +0.5%2.8%7.1 $4.28 8/15/2023358,300 shares $2.04 million +0.3%2.8%6.3 $5.70 7/31/2023357,200 shares $2.60 million +8.9%2.7%5.9 $7.28 7/15/2023327,900 shares $2.33 million +1.1%2.5%4.5 $7.11 6/30/2023324,400 shares $2.36 million +1.8%2.5%4.3 $7.26 6/15/2023318,700 shares $2.38 million -8.1%2.4%4.1 $7.47 5/31/2023346,700 shares $3.29 million +2.5%2.6%4.7 $9.49 5/15/2023338,400 shares $2.72 million -4.1%2.6%5.6 $8.04 4/30/2023352,700 shares $2.65 million -7.9%2.7%6.8 $7.50 4/15/2023382,800 shares $3.12 million +23.5%2.9%8.5 $8.16liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. 3/31/2023309,900 shares $2.36 million +17.9%2.4%6.6 $7.62 3/15/2023262,900 shares $2.12 million -10.0%2.2%5.2 $8.06 2/28/2023292,000 shares $2.13 million -3.3%2.4%5.9 $7.31 2/15/2023301,900 shares $2.42 million -6.0%2.5%5.6 $8.01 1/31/2023321,200 shares $2.63 million -8.7%2.6%4.9 $8.18 1/15/2023351,700 shares $3.29 million -5.8%2.8%5 $9.36 12/30/2022373,300 shares $3.59 million -9.6%2.9%4.8 $9.63 12/15/2022412,700 shares $4.20 million +10.1%3.2%5.1 $10.18 11/30/2022375,000 shares $3.89 million -11.9%3.0%4.3 $10.37 11/15/2022425,800 shares $5.03 million +16.2%3.4%4.5 $11.81 10/31/2022366,400 shares $4.42 million -21.1%2.9%3.5 $12.05 10/15/2022464,400 shares $4.83 million +13.9%3.7%4 $10.41 9/30/2022407,700 shares $4.60 million +28.9%3.2%2.7 $11.28 9/15/2022316,300 shares $3.38 million -4.2%2.5%1.8 $10.68 8/31/2022330,300 shares $4.00 million -9.8%2.6%1.8 $12.11 8/15/2022366,300 shares $4.47 million +31.6%3.0%1.9 $12.19 7/31/2022278,300 shares $2.88 million -2.7%3.3%1.7 $10.34 7/15/2022286,000 shares $4.00 million +22.8%3.4%1.9 $13.98 6/30/2022232,900 shares $2.95 million +61.4%2.8%2.2 $12.68 6/15/2022144,300 shares $1.53 million +65.3%1.7%2 $10.61 5/31/202287,300 shares $790,065.00 -1.0%0.7%1.7 $9.05 5/15/202288,200 shares $620,046.00 +2.3%0.7%2.7 $7.03 4/30/202286,200 shares $639,604.00 +21.4%0.7%3.2 $7.42 4/15/202271,000 shares $590,010.00 -31.2%0.6%2.8 $8.31 3/31/2022103,200 shares $722,400.00 +1.7%0.8%4.5 $7.00 3/15/2022101,500 shares $652,645.00 -1.4%0.8%5 $6.43 2/28/2022102,900 shares $650,328.00 +12.2%0.8%3.7 $6.32 2/15/202291,700 shares $633,647.00 -19.8%0.7%2.6 $6.91 1/31/2022114,300 shares $827,532.00 +13.5%0.9%3 $7.24 1/15/2022100,700 shares $735,110.00 -20.1%0.8%2.4 $7.30 12/31/2021126,000 shares $903,420.00 +17.4%1.0%2.5 $7.17 12/15/2021107,300 shares $743,589.00 -29.8%0.8%2.1 $6.93 11/30/2021152,800 shares $959,584.00 -10.2%1.2%2.9 $6.28 11/15/2021170,100 shares $1.02 million -10.1%1.3%3.6 $6.00 10/29/2021189,100 shares $1.11 million -9.6%1.5%2.8 $5.89 10/15/2021209,100 shares $1.19 million -13.3%1.7%2.3 $5.70 9/30/2021241,300 shares $1.25 million -7.0%1.9%2.3 $5.20 9/15/2021259,500 shares $1.28 million -14.1%2.1%1.5 $4.95 8/31/2021302,100 shares $1.62 million -5.6%2.4%0.9 $5.36 8/13/2021320,000 shares $2.07 million -17.6%2.6%0.9 $6.46 7/30/2021388,500 shares $2.78 million -7.0%3.1%1.1 $7.16 7/15/2021417,900 shares $2.57 million -9.0%3.4%1.3 $6.15 6/30/2021459,100 shares $2.85 million +42.2%3.7%1.3 $6.20 6/15/2021322,800 shares $1.90 million +69.6%2.6%0.8 $5.90 5/28/2021190,300 shares $913,440.00 -12.3%1.5%0.5 $4.80 5/14/2021217,000 shares $1.21 million +17.5%1.7%0.8 $5.56 4/30/2021184,700 shares $971,522.00 +39.8%1.5%0.7 $5.26 4/15/2021132,100 shares $696,167.00 -24.2%1.1%0.4 $5.27 3/31/2021174,300 shares $1.09 million +42.8%1.4%0.5 $6.27 3/15/2021122,100 shares $880,341.00 +62.8%1.0%0.6 $7.21liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. 2/26/202175,000 shares $579,000.00 -24.8%0.6%0.4 $7.72 2/12/202199,700 shares $1.04 million -11.0%0.8%0.6 $10.41 1/29/2021112,000 shares $1.09 million +31.0%1.0%0.7 $9.76 1/15/202185,500 shares $1.37 million No Change0.7%0.5 $15.99 1/15/2020100 shares $183.00 -98.7%N/A0 $1.83 12/31/20197,800 shares $15,912.00 -29.1%0.1%2.6 $2.04 PRPH Short Interest - Frequently Asked Questions What is ProPhase Labs' current short interest? Short interest is the volume of ProPhase Labs shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 144,900 shares of PRPH short. Learn More on ProPhase Labs' current short interest. What is a good short interest ratio for ProPhase Labs? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PRPH shares currently have a short interest ratio of 1.0. Learn More on ProPhase Labs's short interest ratio. Is ProPhase Labs' short interest increasing or decreasing? ProPhase Labs saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 144,900 shares, a decrease of 41.0% from the previous total of 245,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ProPhase Labs' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ProPhase Labs: OptiNose, Inc. (4.88%), Annovis Bio, Inc. (9.49%), Janone Inc. (0.61%), RAPT Therapeutics, Inc. (3.92%), Immix Biopharma, Inc. (2.87%), Eliem Therapeutics, Inc. (2.22%), IO Biotech, Inc. (0.10%), Kronos Bio, Inc. (1.30%), Repare Therapeutics Inc. (2.00%), Galectin Therapeutics Inc. (13.54%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short ProPhase Labs stock? Short selling PRPH is an investing strategy that aims to generate trading profit from ProPhase Labs as its price is falling. PRPH shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ProPhase Labs? A short squeeze for ProPhase Labs occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRPH, which in turn drives the price of the stock up even further. How often is ProPhase Labs' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRPH, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies OptiNose Short Interest Data Annovis Bio Short Interest Data Janone Short Interest Data RAPT Therapeutics Short Interest Data Immix Biopharma Short Interest Data Eliem Therapeutics Short Interest Data IO Biotech Short Interest Data Kronos Bio Short Interest Data Repare Therapeutics Short Interest Data Galectin Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PRPH) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
